Media Toolkit

2018 Generic Drug Access & Savings in the U.S.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report Summary</td>
<td>2</td>
</tr>
<tr>
<td>Social Media Content</td>
<td>3</td>
</tr>
</tbody>
</table>
REPORT SUMMARY

Feel free to use or adapt for newsletter content, press releases, etc.

Report: Generic Drugs Saved the U.S. $265 Billion in 2017

As in previous years, the tenth edition of this annual report presents the independent findings of IQVIA (formerly IMS Health) regarding the savings from generic prescription drugs.

- In 2017, generics saved the U.S. $265 billion.
- Savings for Medicare amounted to $82.7 billion ($1,952 per enrollee).
- Savings for Medicaid totaled $40.6 billion ($568 per enrollee).

The report provides detailed information on savings by state, payer type, treatment area and other factors, as well as the state of the biosimilars market.

Subtitled, Access in Jeopardy, the report also underscores that these savings are at risk due to three factors:

- **Market imbalance.** The once-abundant list of generic drug purchasers has consolidated into three large buying consortia controlling 90 percent of the market and exerting outsized pricing power over generic manufacturers.
- **Anti-competitive abuses.** Some brand manufacturers are gaming regulations to attain unwarranted extensions of the market monopolies by keeping generic and biosimilar competitors from developing and introducing lower-cost medicines.
- **Policy miscues.** Too many lawmakers in Washington and in state legislatures do not understand the differences between the generic and brand business models and fail to appreciate the disparity between a brand monopoly market and a generic multi-competitor commodity market. Consequently, “one-size-fits-all” laws and regulations have been enacted with unintended and harmful outcomes.

“I believe that this report will inform the conversation, in Washington D.C. and in state capitals, about how to rein in drug prices," writes AAM President and CEO Chester “Chip” Davis, Jr. in his introductory note. "If our shared national goal is to keep prescription medicines accessible, preserving and, indeed, expanding, generic savings must remain a priority."
Social Media Content
We encourage you to mention, share and retweet @accessiblemeds. Mix and match shareable images. Your organization can engage with the suggested content below.

Social Images
Click on each image to download. All images are accessible via Dropbox: https://www.dropbox.com/sh/uyi1ssk2iatvmkw/AAAlq8w4I80gn3kAOM2yD2Ffa?dl=0

#AmericanPatientsFirst
#GRxSavingsReport
#DrugPricing
#Generics
#Biosimilars

Twitter
Facebook
LinkedIn
Find out how #Generics and #Biosimilars are bringing treatments within reach for more Americans in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Generic drugs saved U.S. patients a total of $265 billion in 2017, but there is still work to be done to protect and grow critical access to affordable medications. Learn more in the Association for Accessible Medicines report: http://rxaccessreport.us #GRxSavingsReport

Did you know that 93 percent of generic prescriptions are filled at $20 or less? Learn more with the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Americans had an average $6.06 copay at the pharmacy counter with #Generics. Learn how generics are saving American patients billions at http://rxaccessreport.us #GRxSavingsReport #DrugPricing

Did you know that the average generic copay is $6.06 and that 93% of generic prescriptions are filled at $20 or less? Learn more about generics, biosimilars, savings and access in the new report by Association for Accessible Medicines: http://rxaccessreport.us
Savings from Generics in U.S. Totaled $265.1 Billion in 2017

Did you know that #Generics saved the U.S. $265 billion in 2017? Follow @accessiblemeds & download the new #GRxSavingsReport: http://rxaccessreport.us

Americans saved $265 billion with generic prescriptions. Why it matters http://rxaccessreport.us #GRxSavingsReport #DrugPricing

Savings from generics in the U.S. totaled $265 billion in 2017. Learn more about generics, biosimilars, savings and access in the new report by Association for Accessible Medicines: http://rxaccessreport.us
What are #Biosimilars and how do they contribute to a more affordable health system? Learn more with the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Biosimilars offer great promise in affordability and access to U.S. patients. Learn about the #Biosimilars landscape in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Biosimilars offer great promise in affordability and access to U.S. patients. Learn about the biosimilars landscape in the Association for Accessible Medicines report: http://rxaccessreport.us

Biologic medicines are often the only treatments available for serious illnesses, but are very expensive. Biosimilars can give patients a more affordable option. Learn more: http://rxaccessreport.us

Biosimilars have the potential to improve the quality of life for American patients while saving the health system billions of dollars each year. Learn more about savings and access in AAM’s report: http://rxaccessreport.us
All Payers Benefit from Generic Savings

2017 Generic Savings by Method of Payment

IQVIA’s analysis apportions the $265 billion in savings from generics by method of payment, leading to this estimate of savings breakdown by payer. (This estimate assumes the same price for each prescription, regardless of pay type.)

New #GRxSavingsReport from @accessiblemeds finds generic drugs saved #Medicaid 40.6 billion. Find out more at http://rxaccessreport.us

New #GRxSavingsReport from @accessiblemeds finds generic drugs saved #Medicare $82.7 billion. Find out more at http://rxaccessreport.us

How much did your payer type save in 2017? Learn more in the Association for Accessible Medicines 2018 Access & Savings Report: http://rxaccessreport.us

In 2017, generics generated an average $1,952 in savings for every Medicare enrollee and $568 for every Medicaid enrollee. Find out more in the 2018 Access & Savings Report by Association for Accessible Medicines: http://rxaccessreport.us
#Generics used by seniors account for 1/3 of total savings. Learn about how much each patient age group saved in 2017 in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

How much money did your age group save through generics? View the numbers with the newest report by Association for Accessible Medicines: http://rxaccessreport.us
#Generics saved the U.S. health care system $265b in 2017. Learn which treatment areas saved the most money in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Did you know generic medications for mental health treatment saved patients in the U.S. $42b in 2017? See which other treatment areas have significant savings from generic drugs in the Association for Accessible Medicines report: http://rxaccessreport.us

Learn which treatment areas in the U.S. saved the most money for patients through generic drugs in the Association for Accessible Medicines report: http://rxaccessreport.us
#Generics save us all money by keeping #Rx costs competitive. See how much your state saved in a new @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

How much did your state save with generic prescription drugs in 2017? Check out the Association for Accessible Medicines newest report: http://rxaccessreport.us

Which state saved the most money with generic prescription drugs in 2017? View the Association for Accessible Medicines report to see savings across the nation: http://rxaccessreport.us
How does market imbalance affect the health care industry and generics access? Learn more in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Although the U.S. saved billions in 2017 from generics, savings and access are in jeopardy due to market imbalance. Learn more in the report by Association for Accessible Medicines: http://rxaccessreport.us
Unless anti-competitive abuses are stopped, consumers and patients will never see any meaningful relief at the pharmacy counter. Learn more in the @accessiblemeds GRxSavingsReport: http://rxaccessreport.us

Brand drug companies obstruct generic competition by extending monopolies for their high-priced brand drugs. Learn more in the Association for Accessible Medicines report: http://rxaccessreport.us
Generics are helping patients across the nation afford their medications to live healthy and productive lives. Learn the numbers in the Association for Accessible Medicines 2018 Access & Savings Report: http://rxaccessreport.us
In 2017, brand-name drugs represented only 10% of prescriptions but 77% of prescription spending. Learn more in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

In 2017, #Generics accounted for 9 out of every 10 prescriptions filled in the U.S. Learn more in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

In 2017, brand-name drugs represented only 10% of prescriptions but 77% of prescription spending. Learn more: http://rxaccessreport.us

In 2017, #Generics accounted for 9 out of every 10 prescriptions filled in the U.S. Learn more: http://rxaccessreport.us
Fewer patients abandon their prescriptions at the pharmacy counter with #Generics. Learn more in the @accessiblemeds #GRxSavingsReport: http://rxaccessreport.us

Have you walked away from the pharmacy counter because your brand-name prescription was too expensive? Other Americans have, too. Learn the numbers and how generics offer affordability and access: http://rxaccessreport.us